Sanchita Mourya

Sanchita Mourya currently serves as the Executive Medical Director of Clinical Development at Biomea Fusion, directing clinical strategy for Phase 1 and 2 trials across metabolic and oncology therapeutic areas since January 2022. Prior to this role, Sanchita held the position of Senior Medical Director at Kartos Therapeutics, where responsibilities included designing clinical strategies and overseeing Phase 3 and Phase 2 trials for pipeline assets including Navtemadlin and TL-895. Sanchita's earlier experience includes serving as Associate Medical Director at Ascendis Pharma, where protocol authorship and collaboration with key opinion leaders were pivotal, and contributing to NDA filing for Acalabrutinib at Acerta Pharma. Sanchita began a clinical oncology career at Stanford Health Care and holds an M.D. in Gynecology from Lady Hardinge Hospital and a Doctor of Medicine degree from DMC.